Sorry, you need to enable JavaScript to visit this website.

Risk and reporting for Influenza vaccine

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic event following administration of the vaccine.

Immunisation should be postponed in patients with febrile illness or acute infection.

Vaccination is contraindicated in patients with hypersensitivity to the active substances, to any of the excipients (Sodium chloride, Anhydrous disodium phosphate, Sodium dihydrogen phosphate dehydrate, Potassium chloride, Potassium dihydrogen phosphate, Calcium chloride, Water for injections), or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, polymyxin.

  • Influenza Vaccine (Split Virion, inactivated) may be given at the same time as other vaccines 
  • Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified
  • The immunological response may be diminished if the patient is undergoing immunosuppressant treatment

Due to an increased risk of febrile convulsions, the vaccine is not authorised for use in children aged under 5 years.

Side effects very commonly reported in adults 18 years of age and older were headache, myalgia/general muscle ache, injection site tenderness, injection site pain and malaise.

Side effects very commonly reported in children aged 5 to less than 18 years were headache, myalgia/general muscle ache, injection site pain, injection site erythema/redness, malaise, irritability, injection site swelling/induration, pyrexia/fever.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

Further information on adverse event reporting can be found by clicking here.

Summary of Product Characteristics can be found on electronic Medicines Compendium. (eMC)

Patient information Leaflet can be found on electronic Medicines Compendium (eMC).